Refile: US FDA approves Insmed's lung disease drug
12/08/2025 16:38
Corrects day to Tuesday from Wednesday Aug 12 (Reuters) - The U.S. Food and Drug Administration has approved Insmed's INSM.O oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition. (Reporting by Christy Santhosh and Unnamalai L in Bengaluru; Editing by Sriraj Kalluvila) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Insmed
See all newsAstera Labs, CoreWeave and others rise after Nasdaq-100 inclusion
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex
Brief: Insmed Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings